ERBB2 and breast carcinoma: Thus, in the PIK3CA-mutated refametinib sensitive HCC1954-P cells lapatinib does not decrease AKT phosphorylation, indicating a potential disconnect between HER2 activation and PI3K/AKT signalling, which has been observed previously in breast cancer cell lines [28].